A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy
Public ClinicalTrials.gov record NCT03785184. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Single Arm, Open Label Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy
Study identification
- NCT ID
- NCT03785184
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- venetoclax Drug
- lenalidomide Drug
- dexamethasone Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 28, 2019
- Primary completion
- Aug 21, 2019
- Completion
- Aug 21, 2019
- Last update posted
- Aug 27, 2019
2019
United States locations
- U.S. sites
- 7
- U.S. states
- 4
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope /ID# 212211 | Duarte | California | 91010 | — |
| Marin Cancer Care /ID# 208476 | Greenbrae | California | 94904 | — |
| University of California, Los Angeles /ID# 208516 | Los Angeles | California | 90095 | — |
| Karmanos Cancer Institute /ID# 208805 | Detroit | Michigan | 48201 | — |
| Henry Ford Hospital /ID# 208481 | Detroit | Michigan | 48202 | — |
| Duke University Hospital /ID# 208306 | Durham | North Carolina | 27710 | — |
| UPMC Hillman Cancer Ctr /ID# 208121 | Pittsburgh | Pennsylvania | 15232 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03785184, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 27, 2019 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03785184 live on ClinicalTrials.gov.